Zhejiang Ausun Pharmaceutical (603229.SH) cooperated product Tofacitinib Citrate Tablets obtained overseas marketing approval.
Aoxiang Pharmaceuticals (603229.SH) announced that recently, its partner STADAArzneimittel AG (referred to as "STADA"), a subsidiary of Spirig HealthCare AG, received approval from the Swiss drug regulatory authority to market citrate-tolfenamic acid tablets.
Zhejiang Ausun Pharmaceutical (603229.SH) announced that its partner STADA Arzneimittel AG's subsidiary Spirig HealthCare AG has received approval from the Swiss Drug Agency to market the tablet of Tofacitinib citrate.
Tofacitinib citrate tablet is the world's first approved oral Janus kinase inhibitor, a targeted synthetic disease-modifying antirheumatic drug. It works by inhibiting the JAK signaling pathway within cells, regulating immune response, and is mainly used for the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Related Articles
On February 5, SHOUCHENG (00697) spent HKD 10.69 million to repurchase 5.43 million shares.
On February 5th, Taiwan (09890) spent 1.367 million Hong Kong dollars to repurchase 76,200 shares.
Zijin Mining Group (02899) completed the issuance of zero-coupon convertible bonds with a total amount of 1.5 billion US dollars.
On February 5, SHOUCHENG (00697) spent HKD 10.69 million to repurchase 5.43 million shares.
On February 5th, Taiwan (09890) spent 1.367 million Hong Kong dollars to repurchase 76,200 shares.
Zijin Mining Group (02899) completed the issuance of zero-coupon convertible bonds with a total amount of 1.5 billion US dollars.
